Latest Breaking News On - பெஸிஃபிக் ஆராய்ச்சி - Page 2 : comparemela.com

Why Should We Rescue The Legislative Intent Of The BPCIA? By Peter J. Pitts, Robert Popovian, and Wayne Winegarden What happens when regulatory ambiguity displaces sound scientific guidance, deterring the legislative intent of Congress? This is precisely the situation regarding the FDA changing the regulatory rules of the road regarding a biosimilar’s strength versus its potency. It is a distinction with a difference – with the potential unintended consequence of disincentivizing both the development and uptake of biosimilars. It is also important to consider the implications of the legislative intent of the Biologics Price Competition and Innovation Act of 2009 (BPCIA) and how it can be improved.

United statesFrance generalWayne winegardenPeterj pittsRobert popovianPublic health serviceUniversity of southern california school pharmacyGlobal healthy living foundationDrug administrationPacific research instituteUniversity of paris school medicineBiologics price competitionInnovation actPublic health service actPublic interestParis school